Pda Technical Report 82 [hot]

PDA Technical Report 82: Low Endotoxin Recovery (LER)

Introduction

PDA TR-82 (2018) addresses a critical and often misunderstood analytical phenomenon in pharmaceutical quality control: Low Endotoxin Recovery (LER). LER refers to the situation where endotoxin activity is detectable immediately after spiking a sample but becomes significantly reduced or undetectable after storage, even though the endotoxin is physically present. This creates a dangerous false sense of security, as a product might pass the endotoxin test (BET) while still harboring potentially pyrogenic contaminants.

The TR 82 Protocol Skeleton:

Importantly, these processes are reversible—aggressive extraction (e.g., with detergents or heat) can recover the endotoxin, confirming it was never degraded. pda technical report 82

1. No Safe Threshold: The report does not define what level of LER is "acceptable." Is 24-hour recovery enough? 48? This is left to the manufacturer’s risk assessment.
2. Recombinant Alternatives: TR 82 was published before the widespread availability of highly stable rFC assays. Some newer data suggests rFC may be less susceptible to LER than LAL, but TR 82 treats both as vulnerable.
3. Cost of Compliance: Running a 7-day, multi-temperature LER study for every formulation is expensive and resource-intensive. Many smaller companies ignore TR 82 until a regulatory citation occurs.

Step 1: Gap Analysis Review all marketed and pipeline parenteral products. Flag any containing polysorbates (20 or 80), Cremophor, cyclodextrins, or EDTA. PDA Technical Report 82: Low Endotoxin Recovery (LER)